MedTrace Logo

Prostate Cancer Screening: a Pilot Study

NCT06238661 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4500

Last updated 2026-03-05

No results posted yet for this study

Summary

Prostate Cancer (PCa) is the second most frequently diagnosed tumour and the third most lethal among men in Europe. The lack of precise tools and examinations to precisely diagnose PCa has caused overtreatment of indolent and low-aggressive PCa, while in some other cases, with aggressive disease, diagnosis and treatment are dangerously delayed because cancer could be potentially missed. The present trial aims to study a new pathway to early diagnose PCa with Magnetic Resonance Imaging (MRI) to identify men who will not need treatment and those who will benefit from radical treatment, thus improving disease control and quality of life.

Conditions

Interventions

DIAGNOSTIC_TEST

Urology visit with Risk Calculator and MRI

Patients with PSA ≥3 ng/ml will undergo urology visit with risk calculator and MRI assessment of the prostate

Sponsors & Collaborators

  • San Luigi Gonzaga Hospital

    collaborator OTHER

  • Epidemiology and Screening Unit - CPO, Turin, Italy

    collaborator UNKNOWN

  • ASL TO5

    collaborator UNKNOWN

  • Fondazione del Piemonte per l'Oncologia

    lead OTHER

Principal Investigators

  • Daniele Regge, MD · Fondazione del Piemonte per l'Oncologia

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-17
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06238661 on ClinicalTrials.gov